A Phase 2 interventional study of IMC-A12 and Mitoxantrone in Prostate Cancer, sponsored by Eli Lilly and Company. Completed at 36 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Prostatic Neoplasms by Eli Lilly and Company — 2 open to participants now, 8 under way, 3 of them phase 3. Prostatic Neoplasms · Eli Lilly and Company.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2008, is one of 9 in phase 2, and was the 5th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 20 studies in Prostatic Neoplasms by Eli Lilly and Company are open now, in 10 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 2007; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 142 across the 19 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
3 of the studies in Prostatic Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06229366Eli Lilly and Company[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer-related death in men in the United States. Chemotherapy, either as a single agent or in combination, may lead to clinical response, pain control, and/or improved quality of life. Docetaxel is now the first-line standard therapy for AIPC. Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for pain related to advanced Hormone Refractory Prostate Cancer (HRPC). Hormonal manipulations and docetaxel-based chemotherapy are often effective in metastatic prostate cancer; however, disease becomes refractory to these interventions in the majority of men. Although mitoxantrone continues to be a significant agent in the treatment of HRPC, there exists a need for more efficacious therapy in docetaxel-refractory- AIPC. Because of the potential contribution of Insulin Like Growth Factor Receptor (IGF-IR) and VEGFR-2 mediated pathways in prostate cancer pathogenesis, it is hypothesized that each of these biological agents in combination with mitoxantrone and prednisone will result in clinically meaningful activity in AIPC. Therefore, ImClone plans to conduct a randomized Phase 2 trial to assess the safety and efficacy of IMC-A12 or IMC-1121B (ramucirumab) in combination with mitoxantrone and prednisone in participants with AIPC.
Inclusion Criteria:
The participant must have evidence of progressive disease defined as at least one of the following;
Exclusion Criteria:
The participant must have evidence of progressive disease defined as at least one of the following;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Mitoxantrone · Drug: Prednisone · Biological: IMC-1121B (ramucirumab)
Biological: IMC-A12 · Drug: Mitoxantrone · Drug: Prednisone
IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
Also known as: cixutumumab, LY3012217
Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
Also known as: ramucirumab, IMC-1121B, LY3009806
Composite Progression-free Survival (cPFS)
Defined as the median time from randomization to the earliest of: 1. Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST); 2. Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of \>=2 new lesions; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression) 4. Symptomatic progression (for participants without measurable disease); 5. Other clinical events attributable to prostate cancer that require major interventions; or 6. Death from any cause Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
Time frame: Randomization to composite progressive disease, up to 23.4 months
Summary Listing of Participants Reporting Treatment-Emergent Adverse Events
Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
Time frame: Randomization to 36.3 months
Time to Radiographic Evidence of Disease Progression
Time between date of randomization and earliest date of radiographic progression defined as either: 1. Tumor progression by RECIST; 2. Evidence of progression by bone scan; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression). Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy.
Time frame: Randomization to date of radiographic progression, up to 36.3 months
Prostate Specific Antigen (PSA) Response Rate
PSA response rate is defined as the percentage of participants with a decrease in PSA \>= 50 percent from baseline.
Time frame: Baseline up to data cut-off date (up to 36.3 months)
Composite Progression-free Survival (cPFS) at 6-months
Data presented are the percentage of participants without disease progression at 6 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
Time frame: 6 months
Composite Progression-free Survival (cPFS) at 9-months
Data presented are the percentage of participants without disease progression at 9 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
Time frame: 9 months
Composite Progression-free Survival (cPFS) at 12-months
Data presented are the percentage of participants without disease progression at 12 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
Time frame: 12 months
Overall Survival (OS)
Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive.
Time frame: First dose to death due to any cause up to 36.3 months
Objective Response Rate (ORR)
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
Time frame: Baseline to date of progressive disease or death up to 36.3 months
Maximum Concentration (Cmax) at Study Day 1
Maximum Concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 1
Maximum Concentration (Cmax) at Study Day 15
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 15
Maximum Concentration (Cmax) at Study Day 16
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 16
Maximum Concentration (Cmax) at Study Day 30
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 30
Minimum Concentration (Cmin) at Study Day 1
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 1
Minimum Concentration (Cmin) at Study Day 15
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 15
Minimum Concentration (Cmin) at Study Day 16
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 16
Minimum Concentration (Cmin) at Study Day 30
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
Time frame: Day 30
| Milestone | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Started | 69 | 69 |
| Received any quantity of study drug | 66 | 66 |
| Completed | 65 | 66 |
| Not completed | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Never treated: adverse event | 2 | 3 |
| Withdrew: Never treated: progressive disease | 1 | 0 |
Defined as the median time from randomization to the earliest of: 1. Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST); 2. Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of \>=2 new lesions; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression) 4. Symptomatic progression (for participants without measurable disease); 5. Other clinical events attributable to prostate cancer that require major interventions; or 6. Death from any cause Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
| months | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Composite Progression-free Survival (cPFS) | 4.1 (2.2 to 5.6) | 6.7 (4.5 to 8.3) |
Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.
| participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| A12/1121B Related TEAE | 64 | 63 |
| A12/1121B Related Serious TEAE | 22 | 16 |
| A12/1121B Related Grade >= 3 TEAE | 35 | 31 |
| TEAE Leading to Dose Modification of A12/1121B | 35 | 35 |
| TEAE Leading to Discontinuation of A12/1121B | 18 | 25 |
Time between date of randomization and earliest date of radiographic progression defined as either: 1. Tumor progression by RECIST; 2. Evidence of progression by bone scan; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression). Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy.
| months | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Time to Radiographic Evidence of Disease Progression | 7.5 (4.8 to 10.1) | 10.2 (7.5 to 12.6) |
PSA response rate is defined as the percentage of participants with a decrease in PSA \>= 50 percent from baseline.
| percentage of participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Prostate Specific Antigen (PSA) Response Rate | 18.5 (9.3 to 31.4) | 21.4 (11.6 to 34.4) |
Data presented are the percentage of participants without disease progression at 6 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
| percentage of participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Composite Progression-free Survival (cPFS) at 6-months | 37.2 (25.0 to 49.4) | 59.2 (45.8 to 70.4) |
Data presented are the percentage of participants without disease progression at 9 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
| percentage of participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Composite Progression-free Survival (cPFS) at 9-months | 20.7 (11.2 to 32.1) | 35.9 (23.4 to 48.5) |
Data presented are the percentage of participants without disease progression at 12 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.
| percentage of participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Composite Progression-free Survival (cPFS) at 12-months | 12.4 (5.2 to 22.9) | 20.0 (10.1 to 32.3) |
Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive.
| months | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Overall Survival (OS) | 10.8 (6.5 to 13.0) | 13.0 (9.5 to 16.0) |
Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.
| percentage of participants | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| Objective Response Rate (ORR) | 15.2 (6.3 to 28.9) | 31.6 (17.5 to 48.7) |
Maximum Concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | — | 40/66 (60.6%) | 65/66 (98.5%) |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | — | 36/66 (54.5%) | 66/66 (100%) |
| Event | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| DISEASE PROGRESSIONGeneral disorders | 8/66 | 2/66 |
| MEDICATION ERRORInjury, poisoning and procedural complications | 0/66 | 4/66 |
| DEHYDRATIONMetabolism and nutrition disorders | 4/66 | 1/66 |
| BACK PAINMusculoskeletal and connective tissue disorders | 4/66 | 1/66 |
| DIARRHOEAGastrointestinal disorders | 3/66 | 1/66 |
| EXPIRED DRUG ADMINISTEREDInjury, poisoning and procedural complications | 0/66 | 3/66 |
| SYNCOPENervous system disorders | 3/66 | 0/66 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 2/66 | 2/66 |
| LEUKOPENIABlood and lymphatic system disorders | 1/66 | 2/66 |
| NEUTROPENIABlood and lymphatic system disorders | 2/66 | 1/66 |
| Event | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone |
|---|---|---|
| FATIGUEGeneral disorders | 48/66 | 47/66 |
| WEIGHT DECREASEDInvestigations | 43/66 | 40/66 |
| ANOREXIAMetabolism and nutrition disorders | 35/66 | 31/66 |
| NAUSEAGastrointestinal disorders | 34/66 | 31/66 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 31/66 | 8/66 |
| DIARRHOEAGastrointestinal disorders | 29/66 | 29/66 |
| NEUTROPENIABlood and lymphatic system disorders | 28/66 | 24/66 |
| CONSTIPATIONGastrointestinal disorders | 27/66 | 24/66 |
| ANAEMIABlood and lymphatic system disorders | 23/66 | 23/66 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 12/66 | 23/66 |
Modified intent to treat population (mITT): All participants who received any quantity of study drug.
| Age, Categorical(Participants) | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 21 | 51 |
| >=65 years | 36 | 45 | 81 |
| Sex: Female, Male(Participants) | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 66 | 66 | 132 |
| Ethnicity (NIH/OMB)(Participants) | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 65 | 63 | 128 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | Total |
|---|---|---|---|
| White | 61 | 58 | 119 |
| Black Or African American | 4 | 6 | 10 |
| Other | 1 | 2 | 3 |
| Region of Enrollment(participants) | IMC-A12 + Mitoxantrone + Prednisone | IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | Total |
|---|---|---|---|
| United States | 66 | 66 | 132 |
The record gives a start of Aug 2008, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 9 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cixutumumab · Ramucirumab